AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18299653 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone inhaler 50 microg (Group B)
Number of subjects: 120
Study 18299653 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (Group C)
Number of subjects: 120
Study 16517328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.5‐microg/kg bolus, 0.5 microg.kg(‐1).h(‐1), n = 10)
Number of subjects: 20
Study 16517328 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (0.5‐microg/kg bolus, 0.4 microg.kg(‐1).h(‐1), n = 10)
Number of subjects: 20
Study 12740541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 85
Study 12740541 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 85
Study 11097662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine 0.5 microg/kg (n = 21)
Number of subjects: 61
Study 11097662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with epinephrine 0.75 microg/kg (n = 21)
Number of subjects: 61
Study 11097662 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% with saline (n = 19)
Number of subjects: 61
Study 9088816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg, three times, at 6 h intervals (23 patients)
Number of subjects: 73
Study 9088816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg, twice, at 12 h intervals (25 patients)
Number of subjects: 73
Study 9088816 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline three times, at 6 h intervals (25 patients)
Number of subjects: 73
Study 1492531 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherically curved stimuli with varying curvatures and contact forces
Number of subjects: 28
Study 1492531 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherically curved stimuli with varying curvatures
Number of subjects: 28
Study 3884025 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 by mouth
Number of subjects: 0
Study 3884025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31331296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound during prenatal care
Number of subjects: 18640
Study 29391311 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (within 2 weeks from education to colonoscopy)
Number of subjects: 130
Study 29391311 — intervention group
Group type: COMPARATOR
Intervention: Group B (more than 2 weeks from education to colonoscopy)
Number of subjects: 130
Study 27814857 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT) in shortened position
Number of subjects: 28
Study 27814857 — intervention group
Group type: COMPARATOR
Intervention: Sham control in neutral position
Number of subjects: 28
Study 24936899 — intervention group
Group type: EXPERIMENTAL
Intervention: G-trainer
Number of subjects: 12
Study 24936899 — intervention group
Group type: COMPARATOR
Intervention: CompuTrainer (stationary cycling)
Number of subjects: 12
Study 24936899 — intervention group
Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 12
Study 22650127 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (cotton sheet moxibustion combined with plum-blossom-needle tapping therapy)
Number of subjects: 120
Study 22650127 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (Acyclovir ointment, Valaciclovir Hydrochloride tablets, Vitamin B1)
Number of subjects: 120
Study 20204256 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin enriched cookie
Number of subjects: 34
Study 20204256 — intervention group
Group type: COMPARATOR
Intervention: Control cookie
Number of subjects: 34
Study 18363746 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 15% ointment
Number of subjects: 503
Study 18363746 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 10% ointment
Number of subjects: 503
Study 18363746 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 503
Study 18363746 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 15% and 10% ointment
Number of subjects: 503
Study 18363746 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E ointments
Number of subjects: 503
Study 16131636 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention (CTI) services
Number of subjects: 96
Study 16131636 — intervention group
Group type: COMPARATOR
Intervention: Usual services (Control)
Number of subjects: 96
Study 12203663 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 150 IU/kg, 3 times a week for 8 weeks
Number of subjects: 34
Study 12203663 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 34
Study 11677109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 4.5
Number of subjects: 16
Study 11677109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine at 1000 mg/m2 days 1 and 8 with carboplatin AUC 5
Number of subjects: 16
Study 9043841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolytic treatment followed by placebo in hospital (pre-hospital group)
Number of subjects: 5469
Study 9043841 — intervention group
Group type: COMPARATOR
Intervention: Pre-hospital thrombolytic treatment (hospital group)
Number of subjects: 5469
Study 7971289 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG uptake in grade 2- and 3-meningiomas
Number of subjects: 60
Study 7971289 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG uptake in tumors of high cellularity
Number of subjects: 60
Study 7971289 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG uptake in meningiomas with elevated Ki-67 proliferation index (above 2%)
Number of subjects: 60
Study 7971289 — intervention group
Group type: EXPERIMENTAL
Intervention: 18FDG uptake in meningiomas with pronounced chromosomal aberrations
Number of subjects: 60
Study 2485056 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily, doubled if BP uncontrolled after 4 weeks.
Number of subjects: 174
Study 2485056 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP uncontrolled after 4 weeks.
Number of subjects: 174
Study 31353846 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) program consisting of seven educational sessions
Number of subjects: 84
Study 31353846 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) program
Number of subjects: 84
Study 31353846 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 29603851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/d of atrasentan
Number of subjects: 161
Study 29603851 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/d of atrasentan
Number of subjects: 161
Study 28520838 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE website plus an easy-to-read advance directive (AD)
Number of subjects: 414
Study 28520838 — intervention group
Group type: COMPARATOR
Intervention: AD alone
Number of subjects: 414
Study 25935897 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition using the volitional help sheet to link emotional eating triggers with strategies for change
Number of subjects: 240
Study 25935897 — intervention group
Group type: COMPARATOR
Intervention: Control condition identifying emotional eating triggers and strategies for change (volitional help sheet)
Number of subjects: 240
Study 23329850 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent dengue vaccine (LATV)
Number of subjects: 113
Study 23329850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 21465320 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP mask
Number of subjects: 81
Study 21465320 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask
Number of subjects: 81
Study 19115644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil anaesthesia
Number of subjects: 20
Study 19115644 — intervention group
Group type: COMPARATOR
Intervention: Propofol/remifentanil anaesthesia
Number of subjects: 20
Study 17186795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate spray 0.05%
Number of subjects: 120
Study 17186795 — intervention group
Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 120
Study 12962529 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day for 12 months (6 months double-blind and 6 months open-label)
Number of subjects: 0
Study 12962529 — intervention group
Group type: COMPARATOR
Intervention: Galantamine 24 mg/day for 6 months (after switching from placebo)
Number of subjects: 0
Study 12962529 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months (double-blind) followed by galantamine 24 mg/day for 6 months (open-label)
Number of subjects: 0
Study 10831024 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (target serum concentration of 75 microg/mL for 2 weeks)
Number of subjects: 12
Study 10831024 — intervention group
Group type: COMPARATOR
Intervention: Placebo (replaced divalproex during the third week)
Number of subjects: 12
Study 9381056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from RBD patients
Number of subjects: 10
Study 9381056 — intervention group
Group type: COMPARATOR
Intervention: Sera from control group
Number of subjects: 10
Study 9381056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from patients with paraneoplastic anti-Hu and anti-Ri antibodies
Number of subjects: 10
Study 8417457 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-modified Schöber technique
Number of subjects: 15
Study 8417457 — intervention group
Group type: EXPERIMENTAL
Intervention: Double inclinometer method
Number of subjects: 15
Study 31742897 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided radiotherapy (IGRT)
Number of subjects: 590
Study 31742897 — intervention group
Group type: COMPARATOR
Intervention: Non-image-guided radiotherapy (non-IGRT)
Number of subjects: 590
Study 29257943 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine 1.8 mL as a buccal injection and 0.2 mL as a palatal injection
Number of subjects: 84
Study 29257943 — intervention group
Group type: COMPARATOR
Intervention: 4% articaine 1.8 mL plus normal saline 0.2 mL as a palatal injection
Number of subjects: 84
Study 29257943 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine 3.6 mL plus normal saline 0.2 mL as a palatal injection
Number of subjects: 84
Study 28271424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Balance (LB)
Number of subjects: 1246
Study 28271424 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1246
Study 25825422 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 units of BTX‐A
Number of subjects: 42
Study 25825422 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of BTX‐A
Number of subjects: 42
Study 25825422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 25825422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 42
Study 22851003 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the SDI-21
Number of subjects: 111
Study 22851003 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the SDI-21
Number of subjects: 111
Study 22026393 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (including atorvastatin, pravastatin, rosuvastatin, simvastatin)
Number of subjects: 32311
Study 22026393 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins for primary prevention
Number of subjects: 32311
Study 22026393 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins for secondary prevention
Number of subjects: 32311
Study 22026393 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-40 mg/day)
Number of subjects: 32311
Study 22026393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 32311
Study 18303246 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration within 3 hours from stroke onset
Number of subjects: 0
Study 18303246 — intervention group
Group type: COMPARATOR
Intervention: Heparin administration within 48 hours from stroke onset
Number of subjects: 0
Study 17154093 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation (20 Gy total dose delivered in 2 Gy daily fractions)
Number of subjects: 0
Study 17154093 — intervention group
Group type: COMPARATOR
Intervention: External irradiation (as monotherapy)
Number of subjects: 0
Study 17154093 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy (orbital radiation with high-dose intravenous steroid pulse treatment)
Number of subjects: 0
Study 12947992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 12947992 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SIT)
Number of subjects: 0
Study 10753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy patch test (APT)
Number of subjects: 75
Study 10753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral food challenges with allergen
Number of subjects: 75
Study 10753020 — intervention group
Group type: COMPARATOR
Intervention: Oral food challenges with placebo
Number of subjects: 75
Study 10753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE in serum
Number of subjects: 75
Study 10753020 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test
Number of subjects: 75
Study 9190240 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate asthma (II group)
Number of subjects: 3
Study 9190240 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe, corticosteroid-dependent asthma (III group)
Number of subjects: 3
Study 9190240 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 3
Study 1558898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (60 mg/os)
Number of subjects: 25
Study 1558898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3891348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d. administered orally from the first postoperative day till angiography)
Number of subjects: 149
Study 3891348 — intervention group
Group type: COMPARATOR
Intervention: Acenocoumarol (initiated on the second to third postoperative day)
Number of subjects: 149
Study 31923189 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Eating intervention
Number of subjects: 732
Study 31923189 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (pamphlets on nutrition education)
Number of subjects: 732
Study 30190206 — intervention group
Group type: EXPERIMENTAL
Intervention: FIREHAWK stent
Number of subjects: 1653
Study 30190206 — intervention group
Group type: COMPARATOR
Intervention: XIENCE stent
Number of subjects: 1653
Study 26525553 — intervention group
Group type: EXPERIMENTAL
Intervention: BG cream with 2-week follow-up (BG1)
Number of subjects: 36
Study 26525553 — intervention group
Group type: EXPERIMENTAL
Intervention: BG cream with 8-week follow-up (BG2)
Number of subjects: 36
Study 26525553 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with 2-week follow-up (MTA1)
Number of subjects: 36
Study 26525553 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA with 8-week follow-up (MTA2)
Number of subjects: 36
Study 24332263 — intervention group
Group type: EXPERIMENTAL
Intervention: RW-SAIL (standardized glycerinated short ragweed sublingual allergen immunotherapy liquid)
Number of subjects: 429
Study 24332263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 22739069 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (measured by activity monitor and questionnaire)
Number of subjects: 35
Study 22739069 — intervention group
Group type: COMPARATOR
Intervention: Self-reported perception of physical and sedentary activities
Number of subjects: 35
Study 22739069 — intervention group
Group type: COMPARATOR
Intervention: Maximal cardiopulmonary exercise test (CPET)
Number of subjects: 35
Study 22739069 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 35
Study 21287468 — intervention group
Group type: EXPERIMENTAL
Intervention: Conferences utilizing small-group discussions
Number of subjects: 170
Study 21287468 — intervention group
Group type: COMPARATOR
Intervention: Traditional conference method (control)
Number of subjects: 170
Study 16729206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcated trial format
Number of subjects: 59
Study 16729206 — intervention group
Group type: COMPARATOR
Intervention: Unitary trial format
Number of subjects: 59
Study 15523350 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 167
Study 15523350 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 167
Study 11422545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy with cognitive counter conditioning
Number of subjects: 0
Study 11422545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy without cognitive counter conditioning
Number of subjects: 0
Study 11422545 — intervention group
Group type: COMPARATOR
Intervention: Waiting list controls
Number of subjects: 0
Study 9413873 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (3 mg/day) for 4 weeks
Number of subjects: 50
Study 9413873 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 50
Study 8492040 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled ileocolonic anastomosis (side-to-side with GIA+TA devices)
Number of subjects: 440
Study 8492040 — intervention group
Group type: COMPARATOR
Intervention: Manual anastomosis (84 interrupted end‐to‐end, 77 continuous end‐to‐end, 82 interrupted end‐to‐side, 91 continuous end‐to‐side)
Number of subjects: 440
Study 3329531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin and nebulized aminoglycoside
Number of subjects: 6
Study 3329531 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 6
Study 30556429 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 53
Study 30556429 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 53
Study 29226626 — intervention group
Group type: COMPARATOR
Intervention: GSK2982772 (0.1-120 mg single ascending doses)
Number of subjects: 0
Study 29226626 — intervention group
Group type: COMPARATOR
Intervention: GSK2982772 (20 mg once daily to 120 mg twice daily for 14 days)
Number of subjects: 0
Study 29226626 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 (20 mg tablets vs capsules)
Number of subjects: 0
Study 29226626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26474630 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 60
Study 26474630 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 24427279 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day DHA from 16 wk gestation to delivery
Number of subjects: 270
Study 24427279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 22930173 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypectomy during insertion and withdrawal (Group A)
Number of subjects: 301
Study 22930173 — intervention group
Group type: COMPARATOR
Intervention: Polypectomy during withdrawal only (Group B)
Number of subjects: 301
Study 18952910 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin alone
Number of subjects: 18
Study 18952910 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg ABT‐335 alone
Number of subjects: 18
Study 18952910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 40 mg rosuvastatin and 135 mg ABT‐335
Number of subjects: 18
Study 18952910 — intervention group
Group type: COMPARATOR
Intervention: All 3 regimens
Number of subjects: 18
Study 17679016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b 250 microg subcutaneously every other day for 2 years
Number of subjects: 468
Study 17679016 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (placebo)
Number of subjects: 468
Study 16250039 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus UDCA
Number of subjects: 265
Study 16250039 — intervention group
Group type: COMPARATOR
Intervention: UDCA plus placebo
Number of subjects: 265
Study 12414411 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% applied four times daily for 3 days before surgery
Number of subjects: 89
Study 12414411 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3% applied 1 hour before surgery
Number of subjects: 89
Study 10203198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression combined with standard physiotherapy
Number of subjects: 37
Study 10203198 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy alone (Control)
Number of subjects: 37
Study 8525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 52
Study 8525170 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime-amikacin
Number of subjects: 52
Study 2156597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (3 g/m2 plus 3 g/m2 of mesna)
Number of subjects: 110
Study 2156597 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (8 mg/m2)
Number of subjects: 110
Study 2156597 — intervention group
Group type: COMPARATOR
Intervention: MVP arm (Mitomycin plus vindesine and cisplatin)
Number of subjects: 110
Study 2156597 — intervention group
Group type: EXPERIMENTAL
Intervention: IVP arm (Ifosfamide plus vindesine and cisplatin)
Number of subjects: 110
Study 120538 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 120538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 0
Study 31791688 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 and carboplatin AUC5 or AUC6 every 3 weeks (Group 2)
Number of subjects: 1566
Study 31791688 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 and carboplatin AUC2 (Group 3)
Number of subjects: 1566
Study 31791688 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 3-weekly chemotherapy (Group 1)
Number of subjects: 1566